The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients
Open accessAbstract
Background: Breast cancer patients with tumors that are estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive have lower risks of mortality after their diagnosis compared to women with ER- and/or PR-negative disease. However, few studies have evaluated variations in the risks of breast cancer-specific mortality across ER/PR status by either demographic or clinical characteristics. Methods: Using data from 11 population-based cancer registries that participate in the SEER (Surveillance, Epidemiology, and End Results) program, 155,175 women at least 30 years old with a primary diagnosis of invasive breast carcinoma from 1990 to 2001 were included in the study. Associations between joint hormone receptor status and breast cancer mortality risk within categories of diagnosis age, diagnosis year, race/ethnicity, histologic tumor type, stage, grade, size, and axillary lymph node status were evaluated using the Cox proportional hazards model. Results: Compared to ER+/PR+ cases, elevations in risk of mortality were observed across all subcategories of age at diagnosis, ranging from 1.2- to 1.5-fold differences for ER+/PR- cases, 1.5- to 2.1-fold differences for ER-/PR+ cases, and 2.1- to 2.6-fold differences for ER-/PR- cases. Greater differences were observed in analyses stratified by grade; among women with low-grade lesions, ER-/PR- patients had a 2.6-fold (95% confidence interval [CI] 1.7 to 3.9) to 3.1-fold (95% CI 2.8 to 3.4) increased risk of mortality compared to ER+/PR+ patients, but among women with high-grade lesions, they had a 2.1-fold (95% CI 1.9 to 2.2) to 2.3-fold (95% CI 1.8 to 2.8) increased risk. Conclusion: Compared to women with ER+/PR+ tumors, women with ER+/PR-, ER-/PR+, or ER-/PR- tumors experienced higher risks of mortality, which were largely independent of the various demographic and clinical tumor characteristics assessed in this study. The higher relative mortality risks identified among ER-/PR- patients with small or low-grade tumors raise the question of whether there may be a beneficial role for adjuvant chemotherapy in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
The Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Bardou, V.-J., Arpino, G., Elledge, R. M., Osborne, C. K., & Clark, G. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.099 · Cited by 752
IARC Handbooks of Cancer Prevention: Breast cancer screening
Feig, S. A. (2003) · Cancer · doi:10.1002/cncr.11334 · Cited by 742
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1658 · Cited by 731
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.576 · Cited by 697
Prognostic and Predictive Factors in Early-Stage Breast Cancer
Cianfrocca, M., & Goldstein, L. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-606 · Cited by 637
Clinical characteristics of different histologic types of breast cancer
Li, C. I., Uribe, D. J., & Daling, J. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602787 · Cited by 598
Self-citationA Primer and Comparative Review of Major U.S. Mortality Databases
Cowper, D. C., Kubal, J. D., Maynard, C., & Hynes, D. M. (2002) · Annals of Epidemiology · doi:10.1016/s1047-2797(01)00285-x · Cited by 486
Steroid hormone receptors in breast cancer management
Osborne, C. K. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006132427948 · Cited by 438
Fisher, B., Redmond, C., Fisher, E. R., & Caplan, R. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.7.1076 · Cited by 419
Elledge, R. M., Clark, G. M., Chamness, G. C., & Osborne, C. K. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.9.705 · Cited by 414
Fisher, B., Jeong, J.-H., Bryant, J., Anderson, S., Dignam, J., Fisher, E. R., & Wolmark, N. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16981-x · Cited by 359
Li, C. I., Malone, K. E., & Daling, J. R. (2002) · PubMed · Cited by 245
Self-citationIncidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998
Li, C. I., Daling, J. R., & Malone, K. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.088 · Cited by 245
Self-citationHormone receptor status and survival in a population‐based cohort of patients with breast carcinoma
Grann, V. R., Troxel, A. B., Zojwalla, N. J., Jacobson, J. S., Hershman, D., & Neugut, A. I. (2005) · Cancer · doi:10.1002/cncr.21030 · Cited by 229
NCCN Invasive Breast Cancer Clinical Practice Guidelines in Oncology
_, _. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.0025 · Cited by 196
Parl, F. F., Schmidt, B. P., Dupont, W. D., & Wagner, R. K. (1984) · Cancer · Cited by 146
Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers
Pichon, M., Broët, P., Magdelénat, H., Delarue, J., Spyratos, F., Basuyau, J., Saez, S., Rallet, A., Courriere, P. H., Millon, R., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.291 · Cited by 141
Anderson, W. F., Chu, K. C., Chatterjee, N., Brawley, O. W., & Brinton, L. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.18 · Cited by 140
Using the National Death Index to obtain underlying cause of death codes.
Sathiakumar, N., Delzell, E., & Abdalla, O. (1998) · Journal of Occupational & Environmental Medicine · doi:10.1097/00043764-199809000-00010 · Cited by 109
Estrogen receptor determination and long term survival of patients with carcinoma of the breast.
Crowe, J. P., Gordon, N. H., Hubay, C. A., Shenk, R. R., Zollinger, R. M., Brumberg, D. J., Wl, M., & Shuck, J. M. (1991) · PubMed · Cited by 64
Costa, S. D., Lange, S., Klinga, K., Merkle, E., & Kaufmann, M. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00067-9 · Cited by 60
Bernoux, A., de Crémoux, P., Lainé‐Bidron, C., Martin, E., Asselain, B. J. R., & Magdelénat, H. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006011328655 · Cited by 52
Hormone Receptors as Prognostic Factors in Female: Breast Cancer
Aaltomaa, S. H., Lipponen, P., Eskelinen, M. J., Kosma, V.-M., Marin, S., Alhava, E. M., & Syrjänen, K. J. (1991) · Annals of Medicine · doi:10.3109/07853899109148097 · Cited by 49
Survival of women with node negative breast cancer in the Auckland region.
Lethaby, A., Mason, B., Vj, H., et al. (1996) · PubMed · Cited by 37
Smith, R. E., & Good, B. C. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100347 · Cited by 23
Cited by
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Patnaik, J. L., Byers, T., DiGuiseppi, C., Dabelea, D., & Denberg, T. D. (2011) · Breast Cancer Research · doi:10.1186/bcr2901 · Cited by 872
Prat, A., Cheang, M. C. U., Martín, M., Parker, J. S., Carrasco, E., Caballero, R., Tyldesley, S., Gelmon, K., Bernard, P. S., Nielsen, T. O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4134 · Cited by 587
Health and Racial Disparity in Breast Cancer
Yedjou, C. G., Sims, J. N., Miele, L., Noubissi, F., Lowe, L., Fonseca, D. D., Alo, R. A., Payton, M., & Tchounwou, P. B. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_3 · Cited by 509
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
Dai, X., Xiang, L., Li, T., & Bai, Z. (2016) · Journal of Cancer · doi:10.7150/jca.13141 · Cited by 440
Metadata
- Authors
- Dunnwald, L. K., Rossing, M. A., & Li, C. I.
- Venue
- Breast Cancer Research
- Published
- 2007-01-19
- Volume
- 9
- Issue
- 1
- Pages
- R6-R6
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1881540319
- Cited by
- 785
- References
- 31
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.